Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration has approved its first-in-human Investigational New Drug (IND) application for LBL-047.
LBL-047 is a bispecific fusion protein composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain, both independently developed by Leads Biolabs.
Currently, there are no approved clinical trials worldwide targeting both BDCA2 and TACI. With its unique mechanism of action, LBL-047 demonstrates strong first-in-class potential.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.